PLATINUM-BASED CHEMOTHERAPY WITH CONCURRENT THORACIC RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Cisplatin and docetaxel (DP), cisplatin and vinorelbine (CV), calboplatin and paclitaxel (CbP) are optimal regimens for locally advanced non-small-cell lung cancer (LA-NSCLC).

Patients and methods

We retrospectively analyzed the effectiveness and safety of DP, CV and CbP with the concurrent thoracic radiotherapy (TRT) in patients with unresectable LA-NSCLC between August 2005 and August 2011.

Results

We identified 76 patients. DP/CV/CbP were undergone in 25/44/7 patients. The median age was 68 years (37–74); male/female, 57/19; PS 0/1, 46/33; Ad/Sq/NOS, 41/29/14; and clinical stage IIB/IIIA/IIIB, 4/32/40. Dose delivery of chemotherapy was 88/92/80% (DP/CV/CbP) and that of TRT was 93/92/99%. Sixty-three patients responded to the therapy, including five CR (2/3/0), 58 PR (19/33/6). Forty-four patients had recurrence (12/27/5). Among them, 21 patients recurred at a local site (8/10/3) and 23 patients at a distant site (4/17/2). Of this, 45 patients developed grade 3 or greater hematological toxicities (10/33/2). Non-hematological toxicities were grade 3 radiation esophagitis in four patients (2/1/1) and grade 3 radiation pneumonitis in seven patients (2/3/2), respectively.

Discussion

The efficacy, dose delivery and safety in DP and CV arms were similar to previous trials.

Related Topics

    loading  Loading Related Articles